Immunic, Inc. (IMUX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
XMUN 
Immunic looks to 2026 data as late-stage MS program advances
Immunic Inc (NASDAQ:IMUX) said on Wednesday it is entering a pivotal phase for its lead multiple sclerosis drug as the biotech company prepares for key clinical readouts that could shape its longer-term growth strategy. The Nasdaq-listed company said it has completed patient enrollment in two late-stage Phase 3 trials of vidofludimus calcium, an oral therapy being tested in relapsing multiple sclerosis (RMS), and expects synchronized top-line results by the end of 2026.
Immunic's long-term treatment hope for multiple sclerosis – ICYMI
Immunic Inc (NASDAQ:IMUX) earlier this week highlighted the long-term clinical potential of its lead compound vidofludimus calcium in treating multiple sclerosis (MS). Speaking to Proactive, Chief Scientific Officer Dr.
Immunic advances MS therapy vidofludimus calcium during Q3 - ICYMI
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about the company's third quarter highlights, with a particular focus on the progress of its oral MS treatment, vidofludimus calcium. Dr Vitt noted the company had a strong presence at the 2025 ECTRIMS conference, presenting important new data from several clinical studies.
Immunic advances MS program with key clinical findings in Q3
Immunic Inc (NASDAQ:IMUX) highlighted positive clinical results for its lead drug candidate, vidofludimus calcium, showing statistically significant improvement in progressive multiple sclerosis (MS), as the company reported its third quarter 2025 financial results and provided a corporate update. At the 41st Congress of ECTRIMS in September, Immunic presented data from the Phase 2 CALLIPER trial, which showed a greater than two-fold probability of 24-week confirmed disability improvement versus placebo in patients with progressive multiple sclerosis (PMS).
Immunic targeting mental and physical challenges facing MS patients - ICYMI
Immunic Inc (NASDAQ:IMUX) Chief Scientific Officer Dr Hella Kohlhof talked with Proactive about the company's research focus on multiple sclerosis (MS), highlighting how Immunic is aiming to address both the physical and mental health challenges faced by patients. Kohlhof explained the strong link between MS and mental health conditions such as depression and anxiety, noting that studies show around 30% of patients experience depression, while 20% experience anxiety.
Immunic highlights multiple sclerosis drug findings at key neurology gathering
Immunic Inc (NASDAQ:IMUX) has presented clinical trial data suggesting its oral therapy, vidofludimus calcium, could help slow disability in patients with progressive multiple sclerosis, a form of the disease that remains difficult to treat. The results were shared at the annual congress of the European Committee for Treatment and Research in Multiple Sclerosis in Barcelona, one of the largest gatherings of neurologists and researchers in the field.
Immunic secures US patent protection for vidofludimus calcium in dose strengths in progressive MS
Immunic Inc (NASDAQ:IMUX) announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) covering dose strengths of its lead asset, vidofludimus calcium (IMU-838), for the treatment of progressive multiple sclerosis (PMS). The patent, tied to application 18/529,946, protects daily dosing of about 10 mg to 45 mg of vidofludimus calcium, including other salt and free acid forms, for patients with primary progressive multiple sclerosis (PPMS) and secondary progressive multiple sclerosis (SPMS).
Immunic reports promising Phase 2 data for lead drug candidate in progressive MS - ICYMI
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about the company's second quarter highlights, with a particular focus on clinical progress in its multiple sclerosis (MS) programs. The headline development was the promising results from the Phase 2 CALLIPER trial of vidofludimus calcium, Immunic's lead asset.
Immunic advances MS drug program with Phase 3 trials fully enrolled
Immunic Inc (NASDAQ:IMUX) said on Thursday it has fully enrolled its twin Phase 3 ENSURE trials for vidofludimus calcium, positioning the company for a major data readout by end-2026 in relapsing multiple sclerosis (RMS). The oral therapy, which activates the Nurr1 nuclear receptor, has shown neuroprotective, anti-inflammatory, and anti-viral properties.
Immunic CEO discusses Phase 2 multiple sclerosis study success - ICYMI
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about new positive data from the company's phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting multiple sclerosis (RRMS). Proactive: Hello you're watching Proactive, I'm joined by Immunic CEO Dr Daniel Vitt.
Immunic reveals long-term data supporting potential of MS drug vidofludimus calcium
Immunic Inc (NASDAQ:IMUX) released new long-term data from an ongoing study showing that its experimental drug, vidofludimus calcium, continues to help patients with relapsing-remitting multiple sclerosis (RRMS) over time. The biotech company said 92.3% of patients remained free of 12-week confirmed disability worsening (CDW) and 92.7% free of 24-week CDW at week 144, based on data representing roughly 952 cumulative treatment years.
Immunic showcases MS drug data at BIO International Convention in Boston - ICYMI
Immunic Inc (NASDAQ:IMUX) chief operating officer Jason Tardio talked with Proactive about the company's participation at the BIO International Convention in Boston and recent clinical developments. Tardio highlighted Immunic's ongoing business development efforts, particularly around its lead asset, vidofludimus calcium, aimed at treating multiple sclerosis (MS).
